Alzamend Neuro (Alzamend Neuro) EPS (Basic) : $-1.89 (TTM As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro EPS (Basic)?

Alzamend Neuro's basic earnings per share (Basic EPS) for the three months ended in Jan. 2024 was $-0.38. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.89.

Alzamend Neuro's EPS (Diluted) for the three months ended in Jan. 2024 was $-0.38. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.89.

Alzamend Neuro's EPS without NRI for the three months ended in Jan. 2024 was $-0.38. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2024 was -1.89.

During the past 3 years, the average EPS without NRI Growth Rate was -45.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Alzamend Neuro's highest 3-Year average EPS without NRI Growth Rate was -36.70% per year. The lowest was -45.10% per year. And the median was -40.90% per year.

Alzamend Neuro EPS (Basic) Historical Data

The historical data trend for Alzamend Neuro's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro EPS (Basic) Chart

Alzamend Neuro Annual Data

Trend

Apr19

Apr20

Apr21

Apr22

Apr23

EPS (Basic)

-0.82

-0.74

-0.89

-2.10

-2.25

Alzamend Neuro Quarterly Data
	Apr19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EPS (Basic)	Get a 7-Day Free Trial													-0.83	-0.47	-0.60	-0.44	-0.38

Alzamend Neuro EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Alzamend Neuro's Basic EPS for the fiscal year that ended in Apr. 2023 is calculated as

Basic EPS (A: Apr. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-14.878	-	0)	/	6.501
	=	-2.29

Alzamend Neuro's Basic EPS for the quarter that ended in Jan. 2024 is calculated as

Basic EPS (Q: Jan. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.662	-	0)	/	7.054
	=	-0.38

EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.89

Alzamend Neuro (NAS:ALZN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Alzamend Neuro EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzamend Neuro (Alzamend Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326

Website

https://www.alzamend.com

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Executives

Ault Milton C Iii	10 percent owner	11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff	officer: Chief Operating Officer	201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman	director, officer: Chief Executive Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath	director	28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson	director	10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne	director	C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser	director, officer: Exec VP and General Counsel	100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun	officer: SVP of Finance	3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram	director	15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien	officer: Chief Financial Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo	director	2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404